On Sept. 21, 2021, the Medicines Patent Pool (MPP) announced that it had signed a licence agreement with Tandem Nano, the University of Liverpool start-up focused on the development of its proprietary long-acting nanosystems platform technology. The non-exclusive, worldwide licence covers the patents and expertise of promising long-acting injectable technologies (LAIs) that could be applied in three disease areas with a high prevalence in low- and middle-income countries (LMICs): malaria, tuberculosis (TB), and hepatitis C (HCV).